Table 2 QLQ – C30 & BR -23 unadjusted scale scores, percentage of subjects with problems & in good condition^a.

C-30 Functional scales^b

Global QOL/general health

340

2

45.3(15.3)

43.7 – 46.9

6.2

10.9

Physical functioning

330

5

52.6(18.8)

50.6 – 54.6

11.2

25.2

Role functioning

340

2

55.1(21.4)

52.7 – 57.5

7.6

39.1

Emotional

323

2

60.3(22.5)

57.7 – 62.9

8.4

45.2

Cognitive

342

4

59.9(23.9)

57.3 – 62.5

5.8

51.2

Social

339

2

61.2(22.7)

58.8 – 63.6

6.5

52.8

C – 30 symptoms/scales^c

Fatigue

331

3

38.9(21.3)

36.5 – 41.3

29.0

13.6

Nausea & vomiting

334

2

30.2(24.5)

27.6 – 32.8

48.5

12.0

Pain

334

2

43.8(21.7)

41.4 – 46.2

20.1

27.5

Dyspnoea

335

1

42.4(27.8)

39.4 – 45.4

18.8

40.0

Sleep disturbance

338

1

42.7(28.2)

39.7 – 45.7

18.3

39.3

Appetite loss

339

1

37.5(28.0)

34.5 – 40.5

25.1

32.7

Constipation

345

1

27.8(28.2)

24.8 – 30.8

42.0

22.0

Diarrhea

343

1

22.1(27.5)

19.1 – 25.1

54.8

19.2

Financial impact

344

1

31.2(25.2)

28.4 – 34.0

29.1

19.8

QOL – BR23: Functional scales^b

Body image

299

4

61.8(23.3)

59.0 – 64.6

7.0

47.8

Sexual functioning

303

2

69.9(23.6)

67.1 – 72.7

1.3

68.0

Sexual enjoyment

221

1

61.5(23.0)

58.3 – 64.7

2.3

70.1

Future perspective

334

1

59.5(31.9)

56.1 – 62.9

11.7

64.7

BR23: Symptom scales^c

Systemic side effects

300

7

40.1(17.5)

38.1 – 42.1

29.3

6.7

Breast symptoms

293

4

35.6(25.4)

32.6 – 38.6

42.3

14.3

Arm symptoms

318

3

38.2(23.4)

35.6 – 40.8

33.0

13.8

Upset by hair loss

331

1

44.8(29.6)

41.6 – 48.0

17.2

40.8